Jonathan Alan Day

US Patent:

8454971, Jun 4, 2013

Filed:

Feb 13, 2008

Appl. No.:

12/527140

Inventors:

Jonathan Day - San Diego CA, US
James Patterson - Bloomington IN, US
Joseph Chabenne - Fishers IN, US
Maria Dimarchi - Carmel IN, US
David L. Smiley - Bloomington IN, US
Richard D. Dimarchi - Carmel IN, US

Assignee:

Indiana University Research and Technology Corporation - Indianapolis IN

International Classification:

A61K 38/26
C07K 14/605

US Classification:

4241981, 530399

Abstract:

Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR).

US Patent:

20220211818, Jul 7, 2022

Filed:

Jan 18, 2022

Appl. No.:

17/577932

Inventors:

- Indianapolis IN, US
John Michael Beals - Solana Beach CA, US
Jonathan Wesley Day - Carmel IN, US
Craig Duane Dickinson - San Diego CA, US
Andrew Ihor Korytko - Oceanside CA, US
Gregory Alan Lazar - Pacifica CA, US

International Classification:

A61K 38/28
C07K 14/62
A61K 38/16
A61K 38/26
C07K 14/00

Abstract:

The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.